About

ATRIDE, a Greek wearable tech startup based in Athens, has emerged from stealth mode, announcing a significant European funding award from the Interregional Innovation Investments Instrument (I3) and the European Innovation Council & SMEs Executive Agency. ATRIDE and its partners have been awarded 3M euros in funding to aid the expansion, validation, and commercialization of their latest innovation in smart clothing: the 'Digilung' shirt. This shirt is designed for people suffering from chronic respiratory diseases, such as COPD, and elite athletes interested in precise physiological performance analytics. The Digilung shirt uses embedded textile and microelectronic sensors to provide personalized care at the point of need. This improves patient outcomes and generates new clinical insights for better disease management. The shirt utilizes proprietary AI/ML tools and sensor designs, advanced nanomaterials, and smart textiles – all integrated into an elegant t-shirt. ATRIDE aims to expand its product portfolio into international markets and usher in a new era of commercial e-textile success. For more information about ATRIDE and their groundbreaking innovations, please visit www.atride.eu.

Solution & Product

ATRIDE is a pioneer in data-driven innovation, committed to transforming the healthcare landscape. ATRIDE's flagship product, an evidence-based clinical grade smart shirt, is a groundbreaking wearable device that revolutionizes COPD care; it is equipped with cutting-edge sensors and real-time data analysis capabilities, providing COPD patients with instant feedback on their breathing patterns and overall lung health. The shirt collects and analyzes real-time data, offering COPD patients and their healthcare providers valuable insights into their condition. This telemonitoring capability is set to transform the way patients and doctors interact, ensuring more proactive care. Users receive immediate feedback on their breathing techniques, helping them optimize their inhalation and exhalation processes to maximize lung function. Advanced data analytics provide comprehensive reports offering valuable information to patients and healthcare professionals, allowing for more informed decision-making and treatment adjustments. This solution reduces healthcare costs associated with COPD by empowering patients with self-management and personalized care; the product can help reduce the frequency of doctor visits and hospitalizations, thereby reducing overall healthcare costs. Improves the daily lives of those affected by the disease by helping COPD patients improve their breathing techniques, leading to increased energy levels, better sleep, and a reduced risk of complications.

Innovation & Scalability

ATRIDE is committed to innovation and scalability. The company is constantly innovating to improve its products and services, and it is also working to develop scalable solutions that can reach a large number of patients and users. Key innovation initiatives: Continuous improvement of the clinical grade smart shirt: ATRIDE is constantly working to refine it, adding new features and improving its performance. Development of new wearable devices: the company is developing other wearable devices that can address other aspects of COPD care or well-being solutions. Investment in AI to develop more advanced data analytics capabilities. Key scalability initiatives: Partnerships with healthcare providers: ATRIDE is partnering with healthcare providers to make its products and services more accessible to patients. Global expansion: ATRIDE is expanding its reach to other countries to make its products and services available to a wider audience. Development of cloud-based solutions: The company is developing cloud-based solutions to make its products and services scalable. Securing R&D and material science innovation partnerships, along with strategic manufacturing partners in Greece, to allow competitive market advantage and scalability

Traction & achievements

Revolutionizing COPD Care with Breakthrough Innovation ATRIDE, a pioneer in data-driven and material science innovation for smart textiles, is shaping the future of COPD care with its groundbreaking clinical grade smart shirt. This innovative wearable device is designed to empower COPD patients to manage their condition effectively and enhance their quality of life. Key Achievements: Developed and launched the smart shirt, a revolutionary wearable device that provides personalized telemonitoring, precision breathing feedback, and data-driven insights to COPD patients. ATRIDE and its partners received the I3 Interregional Innovation Investments instrument fund to support the development of the scientific smart shirt. Developing successful clinical trials that demonstrate the effectiveness of the scientific smart shirt in improving breathing patterns and overall lung health. Formed partnerships with leading healthcare providers to bring the scientific smart shirt to patients worldwide. Impact on COPD Care: Reduces healthcare costs by empowering patients with self-management and personalized care. Improves patient outcomes by helping patients optimize their breathing techniques and reduce complications. Enhances quality of life by providing patients with real-time feedback and data-driven insights to improve their condition.

Team & Why Us

ATRIDE is led by a team of experienced executives with expertise in wearable technologies, material science, analytics, and healthcare. The team's combined knowledge and passion for innovation make them uniquely qualified to develop groundbreaking solutions that address the unmet needs of COPD patients. Key Strengths: Depth of Expertise: The team possesses a deep understanding of wearable technologies, data analytics, and healthcare, enabling them to create innovative solutions both effective and patient-centric. Innovation Drive: The team is driven by a passion for innovation and a commitment to developing solutions that improve patient care and reduce healthcare costs. Patient-Centric Approach: The team prioritizes the needs of patients in every aspect of their lives, ensuring that their solutions are user-friendly and designed to improve patient outcomes. Why ATRIDE? Proprietary Technology: The company owns a proprietary technology that is at the core of the clinical smart shirt, setting it apart from its competitors. Targeted Approach: The company focuses on developing solutions specifically for COPD patients, a growing and underserved market. Scalability: The company's technology is scalable and can be easily adapted to address other respiratory conditions, expanding its reach and impact on a broader patient base. Commitment to Excellence: The company is committed to delivering high-quality products and services that meet the needs of patients and healthcare providers.

Funding Needs

Accelerating Innovation to Transform COPD Care The company seeks a large investment to fuel its growth and expansion plans. The funds will be used to: Expand clinical trials to include more patients in more countries to generate additional data on the scientific smart shirt's effectiveness and further validate its impact, including health economics studies. Develop new product features to enhance the clinical smart shirt's value proposition and make it an even more comprehensive solution for COPD patients. Expand sales and marketing efforts to broaden outreach to healthcare providers and patients, increasing awareness of the scientific smart shirt and driving adoption across the globe. Explore international expansion and opportunities to enter new markets, such as the United States, to enable the company to reach a wider audience, generate additional revenue streams, and establish itself as a global leader in COPD care. With the right investment, ATRIDE is confident in achieving its mission of revolutionizing COPD care and improving the lives of millions of patients worldwide.